By Dr Carole Abigail Harris

Journal articles

Harris CA; Zebic DS; Morris MF; Ferguson T; Goh JC; Martin AJ; Underhill C; Pook DW; Krieger L; Kichenadasse G; Joshi AJ; Subramaniam S; Zhang A; Joshua AM; Toner GC; Vasey PA; Prithviraj P; Stockler MR; Davis ID; Gedye C, 2026, 'Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma', Clinical Genitourinary Cancer, 24, http://dx.doi.org/10.1016/j.clgc.2026.102585

Talmor B; Harris CA; Gianacas C; Pook D; Tan TH; Davis ID; Krieger L; Marx G; Anton A; Sharma S; Goh JC; Xu K; Pranavan G; Dhillon HM; Antonarakis ES; Denmeade SR; Horvath L; Oakes SR; Allen R; Fontela A; Reich E; Crumbaker M; Hurwitz J; Joshua AM, 2026, 'WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide', European Urology Oncology, 9, pp. 472 - 478, http://dx.doi.org/10.1016/j.euo.2026.02.004

Paner GP; Al-Ahmadie H; Gaisa NT; Lopez-Beltran A; Maclean F; Tsuzuki T; Werneck Da Cunha I; Amin MB; Aning J; Aron M; Athanazio D; Bambury RM; Cheng L; Gopalan A; Gulmann C; Guo CC; Harris C; Iyer G; Jimenez RE; Jinzaki M; Kikuchi E; Lal P; Miyai K; Netto GJ; Pan CC; Panebianco V; Van Rhijn BWG; Siefker-Radtke A; Smith SC; Szarvas T; Wobker SE; Kristiansen G; Reis H; Algaba F; Barrett C; Bertz S; Bezerra SM; Birbe R; Chaudhri P; Cho YM; Cimadamore A; Downes MR; Elgeredly N; Fleischmann A; Haider A; Hallam LA; Hartmann A; Hatimy U; Herrera L; Huang J; Jufe L; Kaushal S; Kenny S; Lee H; Leite K; Mayer N; Mccormick C; Mchale T; Montironi R; O'Donnell M; Park YS; Picken M; Sanguedolce F; Shah N; Srigley J; Sauter G; Suzigan S; Swarbrick N; Theodosiou M; Tretriakova M; Trias I; Lopez FV; Van Leenders G; Vlatkovic L; Wang G; Wightman D; Wightman RH; Williamson SR; Ye H; Zhang H, 2025, 'The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder', Advances in Anatomic Pathology, http://dx.doi.org/10.1097/PAP.0000000000000510

Reis H; Al-Ahmadie H; Gaisa NT; Lopez-Beltran A; Maclean F; Tsuzuki T; Werneck Da Cunha I; Amin MB; Aning J; Aron M; Athanazio D; Bambury RM; Cheng L; Gopalan A; Gulmann C; Guo CC; Harris C; Iyer G; Jimenez RE; Jinzaki M; Kikuchi E; Lal P; Miyai K; Netto GJ; Pan CC; Panebianco V; Van Rhijn BWG; Siefker-Radtke A; Smith SC; Szarvas T; Wobker SE; Kristiansen G; Paner GP; Ferran A; Ciara B; Simone B; Bezerra Stephania M; Ruth B; Preeti C; Mee CY; Alessia C; Downes MR; Nadine E; Achim F; Aiman H; Ann HL; Arndt H; Umi H; Loren H; Jiaoti H; Gopa I; Laura J; Seema K; Sarah K; Hojung L; Katia L; Nick M; Christina M; Teresa M; Rodolfo M; Marie O; Soon PY; Maria P; Francesca S; Nigam S; John S; Guido S; Sueli S; Nicole S; Matthew T; Maria T; Isabel T; Funda VL; Van Leenders G; Ljiljana V; Gang W; Daniela W; Wightman RH; Williamson SR; Huihui Y; Hong Z, 2025, 'The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms', American Journal of Surgical Pathology, http://dx.doi.org/10.1097/PAS.0000000000002416

De Santis M; Redorta JP; Nishiyama H; Krawczyński M; Seyitkuliev A; Novikov A; Guerrero-Ramos F; Zukov R; Kato M; Kawahara T; Goeman L; Puente J; Hellmis E; Powles T; Radziszewski P; Gust KM; Vasey P; Bigot P; Fradet Y; Hunting J; Armstrong J; Boulos S; Hois S; Shore ND; Investigators P; Anderson P; Brungs D; Davis I; Glasgow A; Harris C; Parente P; Patel M; Vasey P; Vela I; Zielinski R; Buchegger J; Gust K; Horninger W; Hutterer G; Loidl W; Luger F; Lusuardi L; Pichler R; Ameye F; Goeman L; Joniau S; Roumeguère T; Fradet Y; Izard J; Kulkarni G; Paradis J-B; Saad F; Azzouzi AR; Barthelemy P; Bigot P; Colombel M; Deturmeny J; Lebret T; Robert G; Saint F; Topart D; Bögemann M; Casuscelli J; De Santis M; Feyerabend S; Garcia-Schürmann M; Hatiboglu G; Hegele A; Hellmis E; Keil C; Klier J; Pulte T; Pursche L; Schmitz-Dräger B; Schütz V; Spiegelhalder P; Stagge E; Tosev G; von Klot C; Arai G; Bekku K; Etani T; Hashine K; Inokuchi J; Izumi K; Izumi K; Kamoto T; Kandori S; Kato M; Kawahara T; Kawai N; Kikuchi E; Kimura T; Kitamura H; Kobayashi Y; Kondo Y; Masumori N; Matsuo T; Miyata Y; Mizuno R; Mukai S; Mutaguchi J; Naiki T; Nishimura K; Ohyama C; Okamoto T; Saito K; Sakai H; Sugimoto M; Takamoto A; Tamada S; Tanaka N; Yonese J; Yoshimura K; De Reijke T; Hunting J; Oddens J; Westgeest H; Demkow T; Korożan M; Kozłowski R; Krawczyński M; Kwiatkowski M; Masłowski M; Radziszewski P; Sadowska U; Tupikowski K; Zaucha R; Zdrojowy R; Atduev V; Karyakin O; Kislov N; Kopyltsov E; Komyakov B; Novikov A; Orlov I; Semenov A; Severtsev A; Seyitkuliev A; Smirnov R; Topuzov T; Vasiliev A; Zukov R; Álvarez-Maestro M; Alcaraz A; Almagro-Casado E; Bonfill T; Díaz CC; Rosell LC; Mingorance JID; Cáliz CG; Guerrero-Ramos F; Hadi NH; Imbroda BH; Suáre MH; Calvo JLM; Piédrola JIP; Puente J; Busquets CXR; López JR; Rodríguez-Faba Ó; Roca MT; Mazón FJV; Echaburu JV; Douglas J; Enting D; Jones R; Linch M; Mostafid H; Noon A; Patel K; Patel P; Powles T; Sephton M; Varughese M, 2025, 'Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial', The Lancet, 406, pp. 2221 - 2234, http://dx.doi.org/10.1016/s0140-6736(25)01897-5

Conduit C; Davis ID; Goh JC; Kichenadasse G; Gurney H; Harris CA; Pook D; Krieger L; Parnis F; Underhill C; Adams D; Roncolato F; Joshua A; Ferguson T; Prithviraj P; Morris M; Harrison M; Begbie S; Hovey E; George M; Liow EC; Link EK; McJannett M; Gedye C, 2024, 'A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma', BJU International, 133, pp. 57 - 67, http://dx.doi.org/10.1111/bju.16190

Pook DW; Harris CA; Link E; Goh JC; Parnis F; Gurney H; Kichenadasse G; Underhill C; Torres J; Roncolato F; Inderjeeth AJ; Conduit C; McJannett MM; Davis ID; Gedye C, 2024, 'UNICAB: Cabozantinib in locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or in those unsuitable for immunotherapy (ANZUP 1802)', Journal of Clinical Oncology, 42, http://dx.doi.org/10.1200/JCO.2024.42.4_suppl.428

, 2024, 'Abstracts', Asia-Pacific Journal of Clinical Oncology, 20, pp. 5 - 64, http://dx.doi.org/10.1111/ajco.14111

Caperchione CM; English M; Sharp P; Agar MR; Phillips JL; Liauw W; Harris CA; McCullough S; Lilian R, 2023, 'Exploring the practicality and acceptability a brief exercise communication and clinician referral pathway in cancer care: a feasibility study', BMC Health Services Research, 23, http://dx.doi.org/10.1186/s12913-023-10003-x

Gurney H; Clay TD; Oliveira N; Wong S; Tran B; Harris C, 2023, 'Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia', Asia Pacific Journal of Clinical Oncology, 19, pp. 585 - 595, http://dx.doi.org/10.1111/ajco.14001

Albiges L; Beckermann K; Miller WH; Goh JC; Gajate P; Harris CA; Suárez C; Peer A; Park SH; Stadler WM; Weickhardt AJ; Faust G; Fong PCC; Waddell T; Venugopal B; Yin L; Wang D; Perini RF; Powles T, 2023, 'Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.', Journal of Clinical Oncology, 41, pp. 4553 - 4553, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4553

Gedye C; Harris CA; Stockler MR; Morris M; Ferguson T; Goh JCH; Martin A; Underhill CR; Pook D; Krieger LEM; Kichenadasse G; Joshi AJ; Subramaniam S; Zebic DS; Zhang A; Joshua AM; Toner GC; Vasey PA; Prithviraj P; Davis ID, 2023, '1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)', Annals of Oncology, 34, pp. s1014, http://dx.doi.org/10.1016/j.annonc.2023.09.1116

Caperchione CM; Stolp S; Phillips JL; Agar M; Sharp P; Liauw W; Harris CA; McCullough S; Lilian R, 2022, 'Cancer survivors’ exercise beliefs, knowledge, and behaviors: An Australian National Survey', Asia Pacific Journal of Clinical Oncology, 18, pp. 625 - 633, http://dx.doi.org/10.1111/ajco.13729

Powles T; Tomczak P; Park SH; Venugopal B; Ferguson T; Symeonides SN; Hajek J; Gurney H; Chang YH; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Burgents JE; Xu L; Imai K; Quinn DI; Choueiri TK; Ferguson TR; Lin TP; Chevreau C; Burke JM; Doshi G; Melichar B; Topart D; Oudard S; Kopyltsov E; Hammers HJ; Alva A; Menezes JDJ; Silva AGE; Winquist EW; Hamzaj A; Procopio G; Karaszewska B; Nowakowska-Zajdel EM; Alekseev BY; Gafanov RA; Izmailov A; Semenov A; Afanasyev SG; Lipatov ON; Srinivas S; McDermott D; Kochuparambil ST; Davis ID; Peltola K; Sabbatini R; Chung J; Shkolnik MI; Matveev VB; Gajate Borau P; McCune S; Hutson TE; Dri A; Sales SC; Yeung C; Alcala Castro CM; Bostrom P; Laguerre B; Buttigliero C; de Giorgi U; Fomin EA; Zakharia Y; Hwang C; Singer EA; Yorio JT; Waterhouse D; Kowalyszyn RD; Alfie MS; Yanez Ruiz E; Buchler T; Kankaanranta K; Ferretti G; Kimura G; Nishimura K; Masumori N; Tamada S; Kato H; Kitamura H; Danielewicz I; Wojcik-Tomaszewska J; Sala Gonzalez N; Chiu KY; Atkins MB; Heath E; Rojas-Uribe GA; Gonzalez Fernandez ME; Feyerabend S; Pignata S; Numakura K; Cybulska Stopa B, 2022, 'Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial', Lancet Oncology, 23, pp. 1133 - 1144, http://dx.doi.org/10.1016/S1470-2045(22)00487-9

Caperchione CM; Sharp P; Phillips JL; Agar M; Liauw W; Harris CA; Marin E; McCullough S; Lilian R, 2022, 'Bridging the gap between attitudes and action: A qualitative exploration of clinician and exercise professional's perceptions to increase opportunities for exercise counselling and referral in cancer care', Patient Education and Counseling, 105, pp. 2489 - 2496, http://dx.doi.org/10.1016/j.pec.2021.11.002

Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H, 2022, 'Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review', Immunotherapy, 14, pp. 511 - 520, http://dx.doi.org/10.2217/imt-2021-0225

Kasherman L; Siu DHW; Woodford R; Harris CA, 2022, 'Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future', Cancers, 14, http://dx.doi.org/10.3390/cancers14061406

Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB, 2022, 'Corrigendum to “Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy” [Gait Posture 89 (2021) 178–185](S0966636221002514)(10.1016/j.gaitpost.2021.07.010)', Gait and Posture, 92, pp. 1, http://dx.doi.org/10.1016/j.gaitpost.2021.11.006

Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB, 2021, 'Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy', Gait and Posture, 89, pp. 178 - 185, http://dx.doi.org/10.1016/j.gaitpost.2021.07.010

Gedye C; Pook DW; Krieger LEM; Harris CA; Goh JC; Kichenadasse G; Gurney H; Underhill C; Parnis F; Joshua AM; Ferguson T; Roncolato F; Harrison ML; Begbie S; Morris MF; Hovey EJ; George M; Prithviraj P; Link E; Davis ID; Group AANZUAPCT, 2021, 'Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma.', Journal of Clinical Oncology, 39, pp. 4565 - 4565, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.4565

Gedye C; Joshi AJ; Zhang AY; Martin AJ; Joshua AM; Harris CA; Underhill C; Pook DW; Toner GC; Kichenadasse G; So JY; Goh JC; Morris MF; Lawrence NJ; Ferguson T; Vasey PA; Prithviraj P; Subramaniam S; Stockler MR; Davis ID, 2021, 'Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601).', Journal of Clinical Oncology, 39, pp. tps367 - tps367, http://dx.doi.org/10.1200/jco.2021.39.6_suppl.tps367

Agar M; Caperchione C; Harris C; Liauw W; Lillian R; McCullough S; Phillips J; Sharp P, 2021, 'Bridging the gap between attitudes and action: Opportunities for the cancer care workforce to support exercise counselling and referral', Journal of Science and Medicine in Sport, 24, pp. s13, http://dx.doi.org/10.1016/j.jsams.2021.09.042

Siu H; O’Neill R; Tong M; Hong J; Harris C; Aghmesheh M; GradDipSC ; Hussein H, 2020, '292 Immune checkpoint inhibitor induced overlapping cardiac and neuromuscular toxicities: Highlight of early diagnosis, early initiation of immunosuppressive therapy and multidisciplinary management', Journal for ImmunoTherapy of Cancer, 8, pp. a319 - a319, http://dx.doi.org/10.1136/jitc-2020-sitc2020.0292

Schmidt A; Azad A; Goh J; Harris C; Joshua AM; Weickhardt A; Krieger L, 2019, 'Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options', Asia Pacific Journal of Clinical Oncology, 15, pp. 3 - 10, http://dx.doi.org/10.1111/ajco.13289

Harris CA; Daniels B; Ward RL; Pearson SA, 2017, 'Retrospective comparison of Australia's Pharmaceutical Benefits Scheme claims data with prescription data in HER2-positive early breast cancer patients, 2008-2012', Public Health Research and Practice, 27, http://dx.doi.org/10.17061/phrp2751744

Harris CA; Ward RL; Dobbins TA; Drew AK; Pearson S, 2011, 'The efficacy of HER2-targeted agents in metastatic breast cancer: A meta-analysis', Annals of Oncology, 22, pp. 1308 - 1317, http://dx.doi.org/10.1093/annonc/mdq593

Adelstein BA; Dobbins TA; Harris CA; Marschner IC; Ward RL, 2011, 'A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer', European Journal of Cancer, 47, pp. 1343 - 1354, http://dx.doi.org/10.1016/j.ejca.2011.03.031

Goldstein D; Harris C; Harris C, 2010, 'Tamoxifen use in retroperitoneal fibrosis, case report and review of the literature', Internal Medicine Journal, 40, pp. e5 - e7

Back to profile page